- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Combatting the COVID-19 crisis
June 2020
the Institute's National Drug Discovery Centre.
As the global community tackles the COVID-19 pandemic, we are working with our collaborators on developing diagnostics and finding new drugs and treatments. Our shared goal is to improve healthcare in response to COVID-19, as well as potential future pandemic viruses.
Institute director Professor Doug Hilton AO said the Institute was leveraging its substantial knowledge of infections, immunology and drug discovery, and access to state-of-the-art technologies, to drive research forward.
“We’ve wasted no time in launching innovative programs in collaboration with partners across medical research and commercial sectors, hospitals and universities to address the current COVID-19 pandemic and potential future coronaviral outbreaks,” Professor Hilton said.
Gold standard prevention trial
In May the Institute launched a gold standard clinical trial to assess whether the drug hydroxychloroquine can prevent COVID-19 in high-risk healthcare workers.
COVID SHIELD is a major collaborative effort led by the Institute in partnership with human data science company IQVIA and healthcare providers across the country, including in Victoria, New South Wales, South Australia and the Australian Capital Territory.
Professor Marc Pellegrini, who is co-leading the trial, said rigorous trials of hydroxychloroquine around the world were essential to determine whether it was useful as a preventative therapy for COVID-19.
“COVID SHIELD is an important study because there is currently no definitive evidence from randomised, double-blinded clinical trials to determine whether hydroxychloroquine works, or doesn’t work, as a preventative agent in healthy people,” Professor Pellegrini said.
COVID SHIELD has been rigorously reviewed and approved by an independent NHMRC Human Research Ethics Committee, as well as independently peer-reviewed and endorsed by the Australasian Society of Infectious Diseases and the Melbourne Academic Centre for Health.
To find out more visit our COVID SHIELD FAQs page.
test for COVID-19.
A rapid test for COVID-19
Institute researchers are also working on developing a new diagnostic tool for coronavirus called c-FIND.
The test is being developed to detect infections in people within minutes – much faster than existing tests – and to detect viral infections even if a person shows no symptoms.
Study co-lead Associate Professor Marco Herold said c-FIND could enable rapid, accurate, point-of-care screening at places such as hospitals, clinics and airports.
“Having a test like this would help us to identify, isolate and manage people infected with COVID-19 swiftly and proactively to prevent disease spread."
"It would enable us to screen people who are negative for the virus, which will help us to continue lifting restrictions and resume some normal activities,” Associate Professor Herold said.
“Together with our collaborators from across Australia, we are now applying for funding through the Medical Research Future Fund (MRFF) to take this research to the next level.
"This project is a great example of innovative technology, led by Australian researchers in collaboration with industry to deliver a commercially-viable and competitive product to Australia and the world,” he said.
(left) with Associate Professor Wai-Hong Tham (centre) and
Professor David Komander (right).
Searching for new medicines
Anti-viral drugs that prevent or treat COVID-19 and potential future coronaviruses are being developed by Institute researchers and their collaborators.
Associate Professor Wai-Hong Tham is leading a collaborative consortium from CSL, Affinity Bio, CSIRO, Burnet Institute and Kirby Institute, developing anti-virals that mimic naturally occurring antibodies that provide immunity to COVID-19. The team received $2.5 million in funding from the Australian and Victorian governments.
“Our consortium is searching for antibodies that block the interaction between the ‘lock and key’ system that SARS-CoV-2 uses to invade human lung cells.
"If we can block these proteins’ interactions, we stop the virus infecting a cell,” she said.
“Biologics medicines for COVID-19 could be important tools for preventing infections as well as treating people in the early stages of the disease.”
Professor David Komander received $1 million in funding from the MRFF to search for drugs that block the coronavirus protein PLpro, which could potentially be used to treat people in early stages of COVID-19, as well as to protect people from infection.
“The virus uses PLpro to disable the cell’s in-built ‘burglar alarm’ system, allowing the virus to hide and multiply undetected, particularly in the early stages of infection.
“The virus changes what is called ‘ubiquitin signalling’. In the new Ubiquitin Signalling Division at the Institute, we are perfectly placed to understand the viral proteins and reverse the viruses’ action,” Professor Komander said.
“This in-depth understanding, plus access to facilities such as the National Drug Discovery Centre and the Australian Synchrotron, means we are at the forefront internationally in developing new medicines to tackle potential future disease outbreaks caused by other coronaviruses.”
Tracking immunity to COVID-19
A new blood test developed by Institute researchers for eliminating Plasmodium vivax malaria is now being adapted to track immunity to COVID-19.
Epidemiologist Professor Ivo Mueller, who is leading the research, said the new technique allowed researchers to look in detail at the amounts of different antibodies in the blood to pinpoint whether – and importantly when – a person has been exposed to COVID-19.
“In the next six months we hope to have discovered how these antibodies change over time, meaning we can explore immunity in wider groups in the community, especially in regions where COVID-19 could be spreading undetected,” Professor Mueller said.
Super Content:
Answers to some frequently asked questions about COVID SHIELD, the clinical trial looking at hydroxychloroquine as a preventative therapy for COVID-19.
Australia's first clinical trial to determine whether hydoroxychloroquine can prevent COVID-19 is open. The trial is recruiting frontline and allied healthcare workers from hospitals across the country.
The Australian Government will invest $3M in Walter and Eliza Hall Institute research programs that are developing new classes of medicines for COVID-19.
The NDDC enables medical researchers to access ultra-high throughput screening, fast tracking scientific discoveries into new medicines.